Autoimmune Liver Disease Overlap Syndromes
On this page
Direct answer
Autoimmune liver disease overlap syndromes are conditions in which features of autoimmune hepatitis coexist with primary biliary cholangitis or primary sclerosing cholangitis. The AIH-PBC overlap is the best-described variant, showing raised ALP and GGT alongside raised transaminases and IgG. It is treated with immunosuppression for the hepatitis plus ursodeoxycholic acid for the cholestatic component, and scoring systems help confirm the diagnosis.
What you must remember
- AIH-PBC overlap: features of both diseases, with raised ALP and GGT plus raised transaminases and IgG, and anti-mitochondrial antibody in some patients.
- AIH-PSC overlap: autoimmune hepatitis features with cholangiographic bile duct changes, more often seen in children and young adults, with p-ANCA frequently positive.
- Autoimmune hepatitis serology: ANA and anti-smooth muscle antibodies define the hepatitis component, and higher titres strengthen the diagnosis.
- PBC serology: anti-mitochondrial antibody, directed against PDC-E2, is the hallmark marker of primary biliary cholangitis.
- Histology: interface hepatitis with plasma cells for the hepatitis component, florid duct lesions for PBC, and onion-skin fibrosis for PSC.
- Scoring: the International Autoimmune Hepatitis Group criteria combine autoantibodies, IgG, histology and exclusion of viral hepatitis to assign probability, though they are not formally validated for overlap and the Paris criteria are used for AIH-PBC.
- Cholangiography: MRCP or ERCP shows irregular, beaded intra- and extrahepatic ducts in the sclerosing overlap.
- Treatment: corticosteroids with azathioprine for the autoimmune component, plus ursodeoxycholic acid for the cholestatic component.
Telling the two overlap variants apart
Both overlaps combine autoimmune hepatitis with a biliary disease, but the biliary component, the antibody pattern and the typical patient differ between them. The table sets the two variants side by side, and each row is a feature that the exam frequently uses to frame a stem.
| Feature | AIH-PBC overlap | AIH-PSC overlap |
|---|---|---|
| Cholestatic pattern | Raised ALP and GGT | Raised ALP with duct changes |
| Key antibodies | Anti-mitochondrial in some, plus ANA or ASMA | p-ANCA, plus ANA or ASMA |
| Cholangiography | Normal duct tree | Irregular, beaded intra- and extrahepatic ducts |
| Usual population | Middle-aged women | Children and young adults |
| Main therapy | Immunosuppression plus ursodeoxycholic acid | Immunosuppression, with ursodeoxycholic acid used |
| Advanced disease | Liver transplant considered for decompensation | Liver transplant considered for decompensation |
The biliary component decides the variant, so ALP with irregular duct changes points towards PSC, while ALP with a normal duct tree points towards PBC. Treatment always addresses both the hepatitis and the biliary disease, because neither drug alone controls both components and long-term outcome depends on treating each.
Where the exam tries to catch you
The exam tests whether you recognise overlap when a single marker is negative, and whether you treat both components.
- Trap: dismissing AIH-PBC because anti-mitochondrial antibody is negative Correct: this antibody is absent in a substantial minority, so the overlap is diagnosed by the combined score and histology.
- Trap: treating an overlap with ursodeoxycholic acid alone when transaminases and IgG are high Correct: the autoimmune component needs immunosuppression as well.
- Trap: calling a biliary stricture on MRCP primary sclerosing cholangitis without considering secondary causes Correct: post-surgical, ischaemic and IgG4-related strictures must be excluded first.
Frequently asked questions
What is the most common autoimmune liver overlap syndrome?
AIH-PBC overlap is the best-described of the overlap syndromes, combining autoimmune hepatitis with primary biliary cholangitis. It shows raised ALP and GGT alongside raised transaminases and IgG.
How is AIH-PBC overlap treated?
AIH-PBC overlap is treated with corticosteroids and azathioprine for the autoimmune component, plus ursodeoxycholic acid for the cholestatic component. Immunosuppression alone does not control the biliary disease, and ursodeoxycholic acid alone does not treat the hepatitis.
Which antibodies suggest AIH-PSC overlap?
p-ANCA is commonly positive in AIH-PSC overlap, together with ANA or anti-smooth muscle antibodies from the autoimmune hepatitis component. Cholangiography showing irregular intra- and extrahepatic bile ducts confirms the sclerosing biliary component.
How do scoring systems help diagnose overlap syndromes?
Scoring systems such as the International Autoimmune Hepatitis Group criteria combine autoantibodies, IgG, histology and exclusion of viral hepatitis to assign diagnostic probability. They help when no single antibody settles the diagnosis, but they are not validated for overlap, so the Paris criteria and histology guide AIH-PBC.